<DOC>
	<DOC>NCT01180296</DOC>
	<brief_summary>To evaluate whether daily oral micronized progesterone is effective in preventing recurrent spontaneous preterm birth (RSPB) and whether micronized progesterone use increases maternal serum progesterone levels.</brief_summary>
	<brief_title>Oral Progesterone for Prevention of Preterm Birth</brief_title>
	<detailed_description>To evaluate whether 400 mg daily oral micronized progesterone from 16 to 34 weeks' is effective in preventing recurrent spontaneous preterm birth (RSPB) and whether micronized progesterone use increases maternal serum progesterone levels.</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>pregnant women less than 20 weeks' gestation who had at least one prior spontaneous preterm birth of a liveborn baby between 20 &amp; 0/7 weeks' and 36 &amp; 6/7 weeks' gestation. multiple gestations, the presence of major fetal anomalies, progesterone use in the current pregnancy (ongoing or past), the presence of a cervical cerclage, and the presence of a placenta previa.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Preterm birth, prevention, progesterone, oral</keyword>
</DOC>